Icons / Logo / Facebook Created with Sketch. Icons / Logo / Google Created with Sketch. Icons / Logo / ORCID Created with Sketch. Branding/Logomark minus Citation Combined Shape Icon/Bookmark-empty Icon/Copy Icon/Collection Icon/Close Copy 7 no author result Created with Sketch. Icon/Back Created with Sketch. Match!
  • References (88)
  • Citations (0)
Published on Apr 1, 2019in Annals of clinical and translational neurology 4.66
Claire Leurent2
Estimated H-index: 2
James Goodman3
Estimated H-index: 3
+ 19 AuthorsAnand Viswanathan47
Estimated H-index: 47
(Harvard University)
Objective: Cerebral amyloid angiopathy (CAA) is caused by cerebrovascular deposition of β‐amyloid fragments leading to cerebrovascular dysfunction and other brain injuries. This phase 2, randomized, double–blind trial in patients with probable CAA assessed the efficacy and safety of ponezumab, a novel monoclonal antibody against Aβ1–40. Methods: Thirty‐six participants aged 55–80 years with probable CAA received intravenous placebo (n = 12) or ponezumab (n = 24). The change from baseline to Days...
Published on Dec 1, 2018in Alzheimer's Research & Therapy
Stephen Salloway55
Estimated H-index: 55
(Brown University),
Lee Honigberg9
Estimated H-index: 9
+ 16 AuthorsTobias Bittner7
Estimated H-index: 7
(Hoffmann-La Roche)
We investigated the effect of crenezumab, a humanized anti-amyloid-beta (Aβ) immunoglobulin (Ig)G4 monoclonal antibody, on biomarkers of amyloid pathology, neurodegeneration, and disease progression in patients with mild-to-moderate Alzheimer’s disease (AD). This double-blind, placebo-controlled, randomized phase II study enrolled patients with mild-to-moderate AD and a Mini-Mental State Examination (MMSE) score of 18–26. In part 1 of the study, patients were 2:1 randomized to receive low-dose s...
Published on May 22, 2018in Neurology 8.69
Jeffrey L. Cummings132
Estimated H-index: 132
Sharon Cohen1
Estimated H-index: 1
+ 14 AuthorsFlavia Brunstein5
Estimated H-index: 5
Objective To evaluate the safety and efficacy of crenezumab in patients with mild to moderate Alzheimer disease (AD). Methods In this phase 2 trial, 431 patients with mild to moderate AD 50 to 80 years of age were randomized 2:1 (crenezumab:placebo). Patients received low-dose subcutaneous crenezumab 300 mg or placebo every 2 weeks (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks. Primary outcome measures were change in Alzheimer9s Disease As...
Published on Dec 1, 2017in Alzheimer's Research & Therapy
Susanne Ostrowitzki13
Estimated H-index: 13
Robert Lasser12
Estimated H-index: 12
+ 14 AuthorsPaul Delmar14
Estimated H-index: 14
(Hoffmann-La Roche)
Background Gantenerumab is a fully human monoclonal antibody that binds aggregated amyloid-β (Aβ) and removes Aβ plaques by Fc receptor-mediated phagocytosis. In the SCarlet RoAD trial, we assessed the efficacy and safety of gantenerumab in prodromal Alzheimer’s disease (AD).
Jaren W. Landen7
Estimated H-index: 7
Sharon Cohen3
Estimated H-index: 3
+ 13 AuthorsKejal Kantarci52
Estimated H-index: 52
(Mayo Clinic)
Abstract Introduction Multiple intravenous doses of ponezumab, an anti-amyloid antibody, were evaluated in subjects with mild-to-moderate Alzheimer's disease (AD). Methods In part A, 77 subjects were randomized to ponezumab 0.1, 0.5, or 1 mg/kg (75 treated) and 26 to placebo (24 treated). In part B, 63 subjects were randomized and treated with ponezumab 3 or 8.5 mg/kg and 32 with placebo. Subjects received 10 infusions over 18 months and were followed for 6 months thereafter. Results Ponezumab w...
Published on Jul 1, 2017in Brain 11.81
Andreas Charidimou30
Estimated H-index: 30
(Harvard University),
Gregoire Boulouis16
Estimated H-index: 16
(Harvard University)
+ 5 AuthorsSteven M. Greenberg96
Estimated H-index: 96
(Harvard University)
Abstract Sporadic cerebral amyloid angiopathy is a common, well-defined small vessel disease and a largely untreatable cause of intracerebral haemorrhage and contributor to age-related cognitive decline. The term 'cerebral amyloid angiopathy' now encompasses not only a specific cerebrovascular pathological finding, but also different clinical syndromes (both acute and progressive), brain parenchymal lesions seen on neuroimaging and a set of diagnostic criteria-the Boston criteria, which have res...
Published on May 2, 2017in Neurology 8.69
Norman Relkin44
Estimated H-index: 44
(Cornell University),
Ronald G. Thomas52
Estimated H-index: 52
(UCSD: University of California, San Diego)
+ 11 AuthorsRema Raman45
Estimated H-index: 45
(SC: University of Southern California)
Objective: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia. Methods: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned 390 participants with mild to moderate AD to receive placebo (low-dose albumin) or IVIg (Gammagard Liquid; Baxalta, Bannockburn, IL) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months. The primary cognitive outcome was change from baseline to 18 mon...
Published on Feb 1, 2017in Journal of Neurology, Neurosurgery, and Psychiatry 8.27
Shawn Kile2
Estimated H-index: 2
William J. Au2
Estimated H-index: 2
+ 5 AuthorsAzad Ghassemi1
Estimated H-index: 1
Objective To determine the effect of intravenous immunoglobulin (IVIG) on brain atrophy and cognitive function in mild cognitive impairment (MCI) due to Alzheimer9s disease (AD). Methods 50 participant 50–84 years of age with amnestic MCI were administered 0.4 g/kg 10% IVIG or 0.9% saline every 2 weeks for a total of 5 infusions (2 g/kg total dose) in a randomised double-blinded design. MRI brain was completed at baseline, 12 and 24 months. Cognitive testing was completed at baseline and every 4...
Published on Dec 1, 2016in Alzheimer's Research & Therapy
Veronika Logovinsky8
Estimated H-index: 8
Andrew Satlin17
Estimated H-index: 17
+ 5 AuthorsLars Lannfelt59
Estimated H-index: 59
(Uppsala University)
Background Several monoclonal antibodies for the treatment of Alzheimer’s disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils.
Published on Dec 1, 2016in Alzheimer's Research & Therapy
Marielle Delnomdedieu4
Estimated H-index: 4
Sridhar Duvvuri3
Estimated H-index: 3
+ 6 AuthorsJames W. Kupiec6
Estimated H-index: 6
Background In the First-In-Human (FIH), 39-week, randomized, adaptive design study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with mild-to-moderate Alzheimer’s disease (AD) after infusion of a humanized monoclonal antibody to amyloid β, AAB-003 (NCT01193608; registered 19 August 2010). AAB-003 was developed by modifying bapineuzumab to reduce Fc-receptor-mediated effector function as a strategy to reduce the removal of amyloid from vessel walls associated wi...
Cited By0